ACRUX INVESTOR PRESENTATION

(ASX: ACR)

February 2021

IMPORTANT NOTICE AND DISCLAIMERS

This presentation contains forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'expects', or 'intends' and other similar words that involve risks and uncertainties.

These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place.

Actual results could differ materially depending on factors such as the availability of resources, the results of non-clinical and clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.

Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of our Company, the Directors and our management.

We cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.

We have no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation, except where required by law and under our continuous disclosure obligations.

These forward looking statements are subject to various risk factors that could cause our actual results to differ materially from the results expressed or anticipated in these statements.

2

Topical Generics - an attractive market segment

Market size1

>US$510bn

~US$200bn

~US$16bn2

3

Generic competition

Variable

High competition from many generic drug manufacturers

Limited generic competition given niche market and development complexity

Source:1. US market by dosage form, IQVIA Q3, 2020 MAT, US market sales (US$); 2. Market size for topically applied drugs IQVIA Q1, 2020 MAT, US market sales (US$)

3. IQVIA Global Generic and Biosimilars Trends and Insights - 2018; 4. IQVIA, National Sales Perspectives, January 2019 - Unbranded generic share of dermatology, MAT

Key Investment highlights

Acrux is a revenue generating pharmaceutical company with an extensive product pipeline of topical generic pharmaceuticals nearing additional regulatory and commercialisation milestones

  • ▪ 2 products on market in over 30 countries. Testosterone solution ANDA approved and pending launch

  • ▪ The topical generic market provides attractive returns with low-risk and low development costs for highly specialised drug developers

  • ▪ The size of the topical generic market in the US is ~US$16bn*

  • ▪ 13 topical generic products with an addressable market of ~US$1.1bn*

  • ▪ Licensing deals executed with recurring revenue and milestone payments for selected products

  • ▪ Proven commercialisation strategy to bring a portfolio of products to market

  • ▪ Led by an experienced management team, Acrux possesses unique development and commercialisation know-how and capabilities

  • ▪ TGA approved, Good Manufacturing Practice (GMP) facility with 25 specialised scientists creates a substantial competitive advantage in generic product selection, development and commercialisation

  • ▪ Two products currently sold through licensees in Europe, the United States and other countries

  • ▪ Additional products nearing FDA approval in addition to Testosterone Solution approved in January 2021

  • ▪ 4 product licensing deals executed with 4 different pharma companies for 9 products in CY 2020

  • ▪ Objective to be cash flow positive by end of 2022

* US market by dosage form, IQVIA Q3, 2020 MAT, US market sales (*US12$)months sales to end Q1, 2020 based on IQVIA.

4

IQVIA is formerly Quintiles and IMS Health, Inc., and provides, on a subscription basis, pharmaceutical industry-leading sales data from over 90 countries in a standardised and comparable way.

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Acrux Limited published this content on 25 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 February 2021 23:27:01 UTC.